Volume 71, Issue 3, Pages 381-388 (March 2017) Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial  Thomas J. Johnston, Greg L. Shaw, Alastair D. Lamb, Deepak Parashar, David Greenberg, Tengbin Xiong, Alison L. Edwards, Vincent Gnanapragasam, Peter Holding, Phillipa Herbert, Michael Davis, Elizabeth Mizielinsk, J. Athene Lane, Jon Oxley, Mary Robinson, Malcolm Mason, John Staffurth, Prasad Bollina, James Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Steve Prescott, Alan Paul, Philip Powell, Derek Rosario, Edward Rowe, Jenny L. Donovan, Freddie C. Hamdy, David E. Neal  European Urology  Volume 71, Issue 3, Pages 381-388 (March 2017) DOI: 10.1016/j.eururo.2016.09.040 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Diagram of patient flow through study. KM=Kaplan-Meier; PSA=prostate-specific antigen. European Urology 2017 71, 381-388DOI: (10.1016/j.eururo.2016.09.040) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 (A) Prostate cancer–specific survival and (B) overall survival according to primary treatment groups among ProtecT cases. Death from prostate cancer occurred in two (4%) of the RP and 12 (5%) of the RT group (HR 0.95, CI 95% 0.22–4.12; p=0.94). Death from all causes occurred in four (7%) of the RP and 37 (15%) of the RT group (HR 0.69, 95% CI 0.29–1.67; p=0.41). A significantly greater proportion of the ADT group died from prostate cancer (n=27, 22%) and all causes (n=49, 40%) compared to men treated with radical therapy (p<0.0001). RP=radical prostatectomy; RT=radical radiotherapy; ADT=androgen deprivation therapy; HR=hazard ratio; CI=confidence interval. European Urology 2017 71, 381-388DOI: (10.1016/j.eururo.2016.09.040) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier plots of (A) prostate cancer–specific survival and (B) overall survival among matched ProtecT cases and Anglia Cancer Network (ACN) controls. By the end of the study, 37 matched cases (9%) and 64 controls (16%) died from prostate cancer. Death from all causes occurred in 89 cases (22%) and 103 controls (26%). HR=hazard ratio; CI=confidence interval. European Urology 2017 71, 381-388DOI: (10.1016/j.eururo.2016.09.040) Copyright © 2016 European Association of Urology Terms and Conditions